Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Thursday, 15'th Feb 2024
Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis an
This suspicious congressional trade returned 48% in two months
06:50am, Wednesday, 27'th Dec 2023
Reports of various elected U.S. officials making significant, conveniently timed trades are not, unfortunately, rare. While much focus has been given to Nancy Pelosi and her husband – and indeed, th
This trading bot buys stocks bought by US politicians; Here are its biggest holdings
07:20am, Friday, 22'nd Dec 2023
In May 2022, Quiver Quantitative, an alternative data platform catering to retail investors, introduced a trading bot that mimics the stock purchases made by influential US politicians.
Senator up 30% on this year's two most suspicious trades
08:08am, Wednesday, 13'th Dec 2023
Largely thanks to the efforts of the online investor community, interesting, suspicious, and conveniently timed trades made by elected officials in the U.S. have come under increased scrutiny in recen
Artivion, Inc. (AORT) Q3 2023 Earnings Call Transcript
01:51am, Sunday, 05'th Nov 2023
Artivion, Inc. (NYSE:AORT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Offic
Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
02:37pm, Friday, 13'th Oct 2023
Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contribute positively to revenue and margins but have l
Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
08:05am, Thursday, 14'th Sep 2023
ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the up
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
11:17am, Thursday, 24'th Aug 2023
Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.
Time to Buy These Medical Stocks as Earnings Approach
08:39pm, Monday, 14'th Aug 2023
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?
11:30am, Thursday, 10'th Aug 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posit
Artivion, Inc. (AORT) Q2 2023 Earnings Call Transcript
01:28pm, Saturday, 05'th Aug 2023
Artivion, Inc. (NYSE:AORT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET Company Participants Laine Morgan – Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief
Artivion (AORT) Q2 Earnings and Revenues Top Estimates
07:32pm, Thursday, 03'rd Aug 2023
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.03 per share a year ago.
Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
10:16pm, Wednesday, 19'th Jul 2023
Artivion, Inc. has begun to recover from the fallout after its PROACT trial failure. On-X sales almost doubled the 5-year average range in Q1, and management look to 15% CAGR in sales moving forward.
Artivion, Inc. (AORT) Q1 2023 Earnings Call Transcript
11:49am, Sunday, 07'th May 2023
Artivion, Inc. (NYSE:AORT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Group Pat Mackin - Chief Executive Officer Ashley Le
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results
04:10pm, Thursday, 20'th Apr 2023
ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial result
